Physician profile
Fred H Ingram
NPI 1508969213
$8,143.81
in general payments reported to CMS, 2019-2025
45 companies · $554 in 2025
The $554 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,595 · 2020: $979 · 2021: $2,000 · 2022: $1,570 · 2023: $920 · 2024: $526 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,999.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,756.91 | 2019-2024 | |
| Astellas Pharma US INC | $847.58 | 2019-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $707.64 | 2020-2025 | Slynd |
| Takeda Pharmaceuticals U.S.A., INC. | $470.67 | 2019-2023 | Trintellix |
| Amgen INC. | $369.41 | 2019-2024 | Evenity, Prolia |
| Pfizer INC. | $344.28 | 2019-2025 | |
| Novo Nordisk INC | $312.82 | 2019-2024 | Wegovy, Saxenda |
| Organon LLC | $278.98 | 2021-2025 | Nexplanon |
| Lilly USA, LLC | $261.23 | 2019-2025 | Zepbound |
| Mayne Pharma Commercial LLC | $238.87 | 2021-2025 | |
| Therapeuticsmd, INC. | $213.55 | 2019-2022 | |
| Gynesonics, INC. | $175.00 | 2021 | |
| Daiichi Sankyo INC. | $157.48 | 2020-2022 | |
| Hologic Sales and Service, LLC | $150.78 | 2019-2025 | Novasure, Myosure Tissue Removal Device |
| Radius Health, INC. | $147.26 | 2019-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Ingram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.